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Relatively recently, the discovery and analysis of
three new human herpesviruses, human herpesvirus
(HHV)-6, HHV-7, and Kaposi's sarcoma-associated
herpesvirus (KSHV), also known as HHV-8, has
contributed greatly to our understanding of the
pathogenesis of several common dermatoses. HHV-6
and HHV-7 are closely related b-herpesviruses that
have been linked with roseola (mostly HHV-6),
severe drug eruptions (HHV-6), and pityriasis rosea
(mostly HHV-7). KSHV is a g-herpesvirus that is
now believed to be the long sought after etiologic
agent of Kaposi's sarcoma. The evidence for these
skin disease associations and key ®ndings from recent
basic science investigations on viral pathogenesis are
discussed in this review. In addition, possible thera-
peutic implications of these research studies are
explored. Key words: pityriasis rosea/KSHV/Kaposi's
sarcoma/pathogenesis. Journal of Investigative Dermatology
Symposium Proceedings 6:197±202, 2001
T
he family of human herpesviruses contains eight
members and is subdivided into three subfamilies
(Table I). These include the a-herpesviruses (herpes
simplex virus types 1 and 2 and varicella-zoster virus),
the b-herpesviruses [cytomegalovirus (CMV), human
herpesvirus (HHV)-6, and HHV-7], and the g-herpesviruses
[Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpes-
virus (KSHV), also known as HHV-8]. These subfamilies are based
upon similarities in viral genomes and biologic behavior. For
example, the a-herpesviruses all cause blistering skin diseases,
whereas the g-herpesviruses are distinguished by their potential to
induce cellular proliferation and malignancy. In this review, I will
focus on the skin diseases caused by the three most recently
described human herpesviruses, HHV-6, HHV-7, and KSHV.
Because of their marked similarities, HHV-6 and HHV-7 will be
discussed together.
HHV-6 AND HHV-7
Historical aspects HHV-6 was discovered by Gallo and
colleagues in 1986 (Salahuddin et al, 1986). It was isolated from
the peripheral blood lymphocytes of six individuals with
lymphoproliferative disorders. HHV-6 was named human B-
lymphotropic virus, or HBLV, because it was initially found within
B cells of infected individuals; however, subsequent work revealed
that CD4+ T cells were the major cell type infected by HHV-6
(Lusso et al, 1988; Takahashi et al, 1989). In 1991, two variants of
HHV-6 were differentiated from one another, HHV-6A and
HHV-6B (Schirmer et al, 1991).
HHV-7 was discovered in 1990 by June and colleagues
(Frenkel et al, 1990). Serendipitously, these investigators noted
cytopathic effects in cultures of activated CD4+ T cells isolated
from a healthy individual. This ®nding led to isolation of
HHV-7 and further ultrastructural and genetic characterization.
Of note, the initials of this healthy individual were R.K., and
designation of HHV-7 as RK virus, or an RK HHV-7 strain, is
sometimes mentioned in the virology literature. The genomes
of HHV-7 and both variants of HHV-6 are closely related,
with 20%±75% nucleic acid homology depending on the genes
being compared (Braun et al, 1997; Black and Pellett, 1999).
Epidemiology and disease associations HHV-6 and HHV-
7 are both ubiquitous herpesviruses. Most commonly, HHV-6
infects infants between the ages of 3 and 6 mo as protection
from maternal antibodies wanes (Okuno et al, 1989). By the age
of 3 y, 90% of the U.S. population has been infected with
HHV-6 (Braun et al, 1997). Respiratory transmission among
persons with close contact with one another is the major route
of primary infection.
The peak age of initial infection for HHV-7 is slightly later than
that for HHV-6; the most common age range for infection is
18 mo to 3 y of age (Wyatt et al, 1991). By age 5 y, 90% of the
U.S. population demonstrates evidence of HHV-7 infection (Black
and Pellett, 1999). Similar to HHV-6, HHV-7 is transmitted
among close contacts via the respiratory route.
Primary infection with HHV-6 can either be asymptomatic,
cause roseola (Yamanishi et al, 1988), or be associated with an
unspeci®ed febrile illness of childhood (Chiu et al, 1998). HHV-6B
is the particular subtype associated with roseola (Schirmer et al,
1991). Children with roseola typically present with high fever,
usually without obvious signs of upper respiratory infection. The
onset of the rash classically appears on the third day of fever, often
coinciding with resolution of the fever. The rash of roseola is
characterized by coin-sized erythematous macules or slightly
elevated papules on the head and neck (Fig 1A). Primary infection
with HHV-7 is most often asymptomatic; however, it can also
cause a roseola-like illness in patients (Tanaka et al, 1994).
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Reactivation of HHV-6 and HHV-7 has been reported in
immunocompromised individuals and can lead to widespread
multiorgan infection in these patients (Cone et al, 1993; Drobyski et
al, 1993, 1994; Knox and Carrigan, 1994). Encephalitis, pneumo-
nitis, and hepatitis are most commonly reported. HHV-6A is the
subtype commonly reactivated in AIDS patients (Schirmer et al,
1991); because it infects CD4+ T cells, HHV-6A has also been
postulated as a cofactor in the progression of HIV disease (Lusso and
Gallo, 1995). Interestingly, HHV-6 can clearly be activated from
latency by HHV-7 reactivation (Katsafanas et al, 1996; Tanaka-
Taya et al, 2000). The mechanism for this phenomenon is
unknown.
In 1997, Drago and colleagues reported on the detection of
HHV-7 DNA in the tissue of patients with pityriasis rosea (PR)
(Drago et al, 1997a, b), a common papulosquamous disease that
most often occurs in otherwise healthy young adults (Fig 1B).
Speci®cally, HHV-7 DNA was found in 12 of 12 fresh lesional skin
biopsies, in 12 of 12 peripheral blood mononuclear cell (PBMC)
preparations, and in 12 of 12 cell-free serum samples isolated from
PR patients. By contrast, HHV-7 DNA was detected in no skin
specimens, in 44% of PBMC, and in no sera from healthy
individuals. These investigators have also shown increased serum
levels of IFN-a in PR patients, indicative of acute viral infection,
and viral cytopathic changes noted on culture of PR PBMC. In
summary, these data indicated that HHV-7 reactivation was
occuring during PR.
Subsequent to these initial reports, however, other research
teams have not been successful in establishing a de®nitive link
between PR and HHV-7 (Kempf et al, 1999; Watanabe et al, 1999;
Kosuge et al, 2000). Speci®cally, in one study, no HHV-7 DNA
was detected in 14 formalin-®xed paraf®n-embedded tissues from
lesional skin of PR patients (Kempf et al, 1999). The other two
reported studies to date suggested a possible association of HHV-7
in a subset of PR patients; Watanabe et al (1999) detected HHV-7
DNA in 47% of plasma samples from PR patients, whereas Kosuge
et al (2000) found evidence of HHV-7 antibody increases in a few
(but not in most) PR patients studied.
We have recently reported preliminary ®ndings in abstract form
on the detection of both HHV-7 and HHV-6 DNA by sensitive
nested polymerase chain reaction (PCR) in skin, cell-free plasma,
cell-free serum, and saliva from most patients with PR.1 Plasma and
serum samples from healthy individuals were always negative. Viral
localization studies are currently underway to help expand and
understand the signi®cance of our PCR results.
Recently, three patients have been reported with severe drug±
induced hypersensitivity syndromes associated with systemic HHV-
6 reactivation (Suzuki et al, 1998; Tohyama et al, 1998). All three
had extensive exfoliative dermatitis. Allopurinol and sulfasalazine
were identi®ed as the medications that triggered the eruptions. The
precise role of HHV-6 in these types of cases needs to be further
explored.
Therapeutic implications and future research
directions The HHV±6 disease associations with roseola in
children and widespread organ involvement in immunosuppressed
individuals are well established. Unfortunately, acyclovir and its
derivatives have little antiherpesviral activity against HHV-6 and
HHV-7 (Takahashi et al, 1997). Foscarnet, ganciclovir, and
cidofovir have some activity at high concentrations, but all of
these medications are of limited practical use because of the need to
administer them intravenously or the potentially worrisome side-
effects. Thus, patients with active HHV-6 replication and roseola
should not be treated with antiherpesviral therapy. These drugs,
however, should be considered in patients with end organ
dysfunction or widespread systemic disease. At this time, patients
with PR, whether the association with HHV-7 is con®rmed or
refuted, should also not be treated with antiherpesviral therapy.
Further study is needed to determine the roles of herpesviruses in
the etiologies of both PR and severe drug-induced hypersensitivity
reactions.
KSHV
Historical aspects Moritz Kaposi, a Hungarian born
dermatologist, ®rst described idiopathic multiple pigmented
sarcoma of the skin in 1872 (Fig 1C) (Kaposi, 1872).
Interestingly, Kaposi was ®rst to suggest a possible infectious
1Watanabe et al. Pityriasis rosea (PR) is associated with reactivation of
both human herpesvirus (HHV)-7 and -6 in blood. J Invest Dermatol
114:784, 2000 (abstr.)
Table I. Classi®cation of known human herpesviruses
Subfamily Herpesvirus type Distinguishing features
a Herpes simplex 1
Herpes simplex 2
Varicella-zoster virus
Variable host range, relatively short reproductive cycle, rapid spread in culture, ef®cient destruction of infected cells,
capacity to establish latent infections primarily (but not exclusively) in sensory ganglia
b Cytomegalovirus
HHV-6
HHV-7
Restricted host range, relatively long reproductive cycle, slow growth in culture, infected cells become enlarged,
carrier cultures easily established
g Epstein-Barr virus
KSHV (HHV-8)
Restricted host range, replicate in lymphoblastoid cells and sometimes in epithelioid and ®broblastic cells, latent
virus frequently detected in l ymphoid tissue, associations with malignancies
Figure 1. Clinical examples of the skin
diseases associated with HHV-6, -7, and -8
infection. (A) Roseola, most often associated
with HHV-6 primary infection. (B) PR,
purported to be associated with reactivation of
HHV-7. (C) KS, characterized by tumor spindle
cells latently infected with KSHV, also known as
HHV-8.
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etiology for Kaposi's sarcoma (KS). With the epidemiologic
evidence of KS clustering in characteristic populations and
clinical disease settings (especially as documented in the
HIV+ gay community), the search for a possible infectious cause
of KS intensi®ed (Beral et al, 1990). Many organisms were
purported to be the etiologic agent of KS (reviewed in Blauvelt,
1999), yet evidence for causality was subsequently not
substantiated.
In December 1994, the husband and wife research team of Yuan
Chang and Patrick Moore at Columbia University reported on the
isolation of novel herpesviral DNA sequences in KS tissue, but not
in surrounding normal skin (Chang et al, 1994). The DNA was
detected in a KS genomic library using the powerful molecular
biologic method of representational difference analysis, a technique
that combines features of subtractive hybridization and PCR
(Lisitsyn et al, 1993). Many other studies have now con®rmed the
presence of this virus within all clinical types of KS (reviewed in
Blauvelt, 1999). Thus, KSHV is found within lesions of AIDS-
associated, classical, endemic, and iatrogenic KS, as well as in KS
involving skin, lymph nodes, lungs, or the gastrointestinal tract.
Because of this tight disease association, this new virus became
known as KSHV (currently the preferred term), although some
refer to it as HHV-8.
Epidemiology and disease associations The detection of
antibodies speci®c for KSHV has yielded insight into the
geographic distribution of this virus. Current assays show that
approximately 95% of KS patients (all clinical types) are seropositive
for KSHV (Gao et al, 1996; Kedes et al, 1996; Simpson et al, 1996).
Interestingly, most studies have also shown relatively high levels of
KSHV seropositivity in populations where KS is prevalent. For
example, HIV+ gay men, sub-Saharan Africans, and individuals
from southern Italy who have no clinical evidence of KS, yet all of
whom represent ``at risk'' populations for KS, have a high
incidence of KSHV seropositivity (approximately 30%±40%,
50%±60%, and 15%±30%, respectively) (Gao et al, 1996; Kedes et
al, 1996; Simpson et al, 1996). By contrast, speci®c individuals at
low risk of developing KS (e.g., HIV-infected women and children
from the U.S.A.) have a low prevalence of KSHV-speci®c
antibodies (Simpson et al, 1996; Blauvelt et al, 1997; Kedes et al,
1997). Similarly, the prevalence of KSHV infection in the general
adult population in most areas of the U.S.A. and western Europe is
low (less than 5%) (Gao et al, 1996; Kedes et al, 1996; Simpson et al,
1996).
Documented cases of primary KSHV infection are rare
(Oksenhendler et al, 1998; Marcelin et al, 2000). These patients
have been described as having an infectious mononucleosis-like
syndrome consisting of fever, lymphadenopathy, and splenomegaly.
No rash has yet been reported with primary KSHV infection. By
contrast to this description, Luppi et al recently reported primary
KSHV infection following transplantation; two patients experi-
enced bone marrow failure within months after each receiving
transplanted kidneys from the same KSHV-infected donor (Luppi et
al, 2000). These cases suggest that immunosuppression could alter
normal primary immune responses to KSHV and lead to severe
disease.
In regard to modes of transmission, epidemiologic studies clearly
show that KSHV is a sexually transmitted disease in the gay
community (Martin et al, 1998; O'Brien et al, 1999). Interestingly,
KSHV has been detected within gastrointestinal mucosa of HIV-
positive individuals (Thomas et al, 1996), suggesting a possible basis
for fecal-oral or oral-fecal transmission of KSHV. There are also
clear studies that suggest nonsexual routes of KSHV transmission
(e.g., via saliva), especially in African countries (Andreoni et al,
1999; Rezza et al, 2000). In general, herpesviruses are frequently
detected in saliva of infected individuals. KSHV is no different, in
that this virus has been readily detected in the saliva of most KS
patients and in 15%±33% of HIV+ patients without KS (Koelle et
al, 1997; Pauk et al, 2000). Of possible relevance to transmission,
one study demonstrated that KSHV isolated from saliva of KS
patients was infectious (Viera et al, 1997). The discrepancy in the
mode of KSHV transmission between developed and underdevel-
oped nations is similar to that observed with hepatitis A virus
infection, and suggests that poor hygiene may increase the risk of
acquiring KSHV. Finally, sequence differences among KSHV in
different parts of the world suggest the existence of several KSHV
strains (Poole et al, 1999; Zong et al, 1999). It is theoretically
possible that different KSHV strains may have different routes of
transmission and clinical relevance. Further study is needed to
determine this issue as well as other speci®c variables involved in
the transmission of KSHV and, in particular, studies are needed that
examine these factors in different parts of the world.
In addition to KS, Chang and Moore initially detected KSHV
DNA in three of 27 cases of AIDS-associated lymphomas (Chang et
al, 1994). On subsequent analysis, it was determined that these
patients had primary effusion lymphoma (PEL), a rare disease
previously known as body cavity-based B cell lymphoma
(Cesarman et al, 1995). Patients present with collections of serous
¯uid, usually with no solid tumor mass, within the pleural,
pericardial, or peritoneal cavities; the ¯uid contains malignant
B cells that are infected with KSHV and often dually infected with
EBV. The original report by Cesarman et al that de®nitively linked
KSHV with PEL was con®rmed by many other studies (Nador et al,
1996; Dupin et al, 1999). Importantly, several KSHV-infected B
cell lines have been isolated from patients with PEL and have
allowed investigators to study KSHV gene expression and the viral
life cycle in detail (Sarid et al, 1998; Jenner et al, 2001; Zoeteweij et
al, 2001).
KSHV has also been linked with con®dence to the plasmablastic
variant of Castleman's disease (CD), also called multicentric
angiofollicular lymphoid hyperplasia (Soulier et al, 1995; Dupin et
al, 2000). This variant of CD is typically (but not always) associated
with HIV disease. Clinically, patients with CD present with fever,
lymphadenopathy, and splenomegaly, whereas histologic examin-
ation of affected tissues shows polyclonal lymphoid hyperprolifera-
tion with vascular hyperplasia.
Other than KS, PEL, and CD, there are a fairly large number of
reports on the PCR detection of KSHV DNA in a wide variety of
diseases (reviewed in Blauvelt, 1999). Some of these include
angiosarcoma, a variety of lymphoproliferative disorders, basal cell
carcinoma, pemphigus vulgaris and foliaceus, multiple myeloma,
and sarcoidosis. Subsequently, however, many teams of independ-
ent investigators have been unable to substantiate the claims of
these studies, adding strength to the conclusion that KSHV is
de®nitively linked to only three diseases: KS, PEL, and CD. This
experience has proven that rigorous evaluation of possible future
KSHV disease associations is needed. Because of the great potential
for false positive PCR results, it will be important to prove or
disprove initial PCR reports by performing viral localization studies
within tissue (e.g., electron microscopy, in situ hybridization,
immunostaining) and by examination of patients' sera for KSHV
antibodies.
Pathogenesis of KS Using the techniques of in situ PCR, in
situ hybridization, electron microscopy, and immunohisto-
chemistry, KSHV is localized to tumor spindle cells, lymphatic
endothelial cells lining slit-like vascular spaces, and tumor-
in®ltrating leukocytes (Boshoff et al, 1995; Orenstein et al, 1997;
Dupin et al, 1999). Ultrastructurally, the in®ltrating leukocytes
appear to be lymphocytes (Orenstein et al, 1997), although more
studies will be required to identify the nature of these cells. The
localization studies con®rmed the earlier PCR studies and added
further insight into the role that KSHV may be playing in the
pathogenesis of KS by identifying speci®c cellular targets for viral
infection.
Most studies have now established that KSHV can be found in
the blood of over half of all KS patients (Ambroziak et al, 1995;
Whitby et al, 1995). Speci®cally, virus has been localized to
circulating B cells (Ambroziak et al, 1995; Henry et al, 1999),
although there are a few reports of KSHV within circulating
VOL. 6, NO. 3 DECEMBER 2001 HHV-6, HHV-7, AND KSHV 199
CD34+ cells and CD8+ T cells. Like EBV, B cells appear to be the
major latent reservoir cell for KSHV in blood. Interestingly, the
ability to detect KSHV DNA in peripheral blood leukocytes from
individuals without KS is predictive for future development of KS
(within 2±4 y) (Whitby et al, 1995; Moore et al, 1996). Taken
together, these data suggest that reactivation from latency is
occuring in peripheral blood B cells, perhaps leading to ``seeding''
of virus within dermal lymphatics (Fig 2). Multiple factors are
likely to be involved in regulating latent-to-lytic switching of
KSHV and eventual KS development in a given individual, some of
which include age, sex hormones, concomitant HIV disease, pro-
in¯ammatory and angiogenic cytokines and growth factors,
immunosuppressive drugs, and perhaps other processes that impair
cell-mediated immunity (Fig 2). Interestingly, we have recently
provided evidence that tissue hypoxia (Davis et al, 2001) and
genetic predisposition (Foster et al, 2000; Lehrnbecher et al, 2000)
may also contribute to the onset of KS. Importantly, a complete
understanding of this variety of factors may lead to speci®c
prophylactic interventions in KSHV-infected individuals at risk for
developing KS.
Like EBV, KSHV belongs to the g-herpesvirus subfamily. These
herpesviruses share sequence homology and the ability to infect and
transform lymphocytes (Table I). Although the EBV genes
involved in cellular transformation are well known, there are no
homologous genes within the KSHV genome (Russo et al, 1996).
Instead, KSHV, which contains over 80 open reading frames, has
the striking feature of having many genes that encode for proteins
with interesting cellular homologs (Table II) (Russo et al, 1996);
however, most of these genes have expression patterns limited to
active viral replication, or the lytic life cycle (Sarid et al, 1998;
Jenner et al, 2001). The vast majority of KS tumor spindle cells are
latently (and not lytically) infected by KSHV (Orenstein et al,
1997). Thus far, LANA, v-cyclin, vFLIP, and kaposin are the only
KSHV-encoded genes shown to be expressed in latently infected
KS tumor spindle cells (Table II) (Boshoff et al, 1995; Davis et al,
1997; Dupin et al, 1999; Sturzl et al, 1999). These are the likely
candidate KSHV oncogenes. Among several other functions
(Schwam et al, 2000; Renne et al, 2001), LANA has been shown
to tether KSHV DNA to human chromosomes (Ballestas et al,
1999; Cotter and Robertson, 1999) and to interfere with
functioning of both Rb (Radkov et al, 2000) and p53 (Friborg et
al, 1999), major tumor suppressor proteins. v-Cyclin has been
shown to stimulate resting cells through the cell cycle by
overcoming normal Rb-mediated suppression of the G1, or
resting, phase of the cell cycle (Godden-Kent et al, 1997;
Swanton et al, 1997); v-cyclin has also been shown to interfere
with apoptotic pathways through Bcl-2 binding (Ojala et al, 2000).
Kaposin has been shown to have transforming capabilities, but its
mechanism of action is unknown (Muralidhar et al, 1998;
Muralidhar et al, 2000). Finally, vFLIP may be involved in
preventing apoptosis within KS tumors (Thome et al, 1997).
Identifying the precise functions of these potential viral oncopro-
teins, and determining how they interact with one another, should
lead to a more complete understanding of how KSHV stimulates
cell growth.
Therapeutic implications and future research
directions Knowledge of the KSHV life cycle has important
therapeutic implications for KSHV-infected individuals. For
example, all known antiherpesviral medications, including
acyclovir and its derivatives, foscarnet, cidofovir, and ganciclovir,
act by blocking active viral replication. Because of this, they are
likely to have no signi®cant impact on existing KS lesions, where
the majority of tumor spindle cells are latently infected with KSHV.
By contrast, these drugs may be expected to prevent onset of new
lesions, or perhaps prevent the onset of KS in those who are
infected with KSHV. Indeed, several retrospective analyzes suggest
that HIV+ patients who have taken foscarnet or ganciclovir have a
lower incidence of KS when compared with those who have not
taken these drugs (Costagliola and Mary-Krause, 1995; Jones et al,
1995). Past use of acyclovir was not protective for future
development of KS. Interestingly, but not surprisingly, these
epidemiologic observations have been bolstered by laboratory
reports showing that foscarnet, ganciclovir, and cidofovir, but not
acyclovir, block lytic induction of KSHV in phorbol ester-
stimulated PEL cell lines (Kedes and Ganem, 1997; Zoeteweij et
al, 1999). It is hoped that new treatments for KS will be designed to
speci®cally target the antigens expressed by latently infected cells.
Cellular immune responses directed against KSHV have not been
adequately studied as of yet (Osman et al, 1999; Brander et al, 2000).
The fascinating observation that KS can develop during immuno-
suppressive therapy, and regress following withdrawal of immuno-
suppressive agents, strongly suggests an important role for cell-
mediated immunity in the control of KSHV-induced disease. This
is true for EBV, where loss of EBV-speci®c immunity is linked to
the onset of EBV-associated disease (Rickinson and Moss, 1997). In
HIV-infected individuals, the common occurrence of KS improve-
ment in patients receiving highly active antiretroviral therapy is
likely due to improved cellular immunity, since these drugs have no
direct effect on KSHV replication (Kedes and Ganem, 1997;
Zoeteweij et al, 1999). Delineating the determinants of KSHV-
speci®c cellular immunity should prove useful for both therapeutic
and preventive purposes. For example, advances in this area may
Figure 2. Hypothetical scheme of KS pathogenesis.
Table II. KSHV-encoded genes that may be involved in
growth dysregulation or evasion of immune surveillance
ORFa Name Presumed function
K2b vIL-6 pro-in¯ammatory, block apoptosis
K4 vMIP-II pro-in¯ammatory, angiogenic
K6 vMIP-I pro-in¯ammatory, angiogenic
K9 vIRF growth promotion, block interferon signaling
K12 kaposinc growth promotion
16 vBcl-2 block apoptosis
71 vFLIPc block apoptosis
72 v-cyclinc growth promotion
73 LANAc tethers viral DNA to chromosome, growth promotion
74 GPCR growth promotion, angiogenic
aOpen reading frame, or gene.
bKSHV genes that are not homologous with other herpesvirus genes are prece-
ded with the letter K.
c ``Latent genes'' expressed in the majority of tumor spindle cells.
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lead to strategies designed to boost KSHV-speci®c immunity in KS
patients, or be used to design vaccines to prevent KSHV infection.
Although much has been learned in a relatively short period of
time, much work remains to be done in order to delineate the
precise role of KSHV in the pathogenesis of KS and other diseases.
In vitro infection of normal cells with KSHV has proven dif®cult
(Renne et al, 1998). There is, as of yet, no robust system for
studying de novo KSHV infection and the functional effects
induced by infection, although several investigators have reported
success in infecting endothelial cells, either in the absence (Flore et
al, 1998) or in the presence of other viruses (Cannon et al, 2000) or
viral proteins (Moses et al, 1999). No good animal model for KS
exists, i.e., one that incorporates KSHV infection. Injection of PEL
cells into immunode®cient mice leads to lymphoma-like tumor
formation; however, no transfer of KSHV infection to murine cells
occurs (Picchio et al, 1997; Boshoff et al, 1998). Interestingly,
KSHV-related viruses have recently been identi®ed in nonhuman
primates, with one report linking viral infection with the KS-like
disease retroperitoneal ®bromatosis in the monkey (Desrosiers et al,
1997; Lacoste et al, 2000). The usefulness of these ®ndings as
potential models for KS remains to be determined. Obviously,
development of a small animal model for KS that incorporates
KSHV infection will prove invaluable for studying KS pathogenesis
and for testing new therapeutic reagents.
I thank Harry Schaefer for helping to prepare the ®gures, Robert Silverman for the
picture of the child with roseola, and Takahiro Watanabe for helpful discussions.
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